beta-lactams has been researched along with Cirrhosis in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alispahic, IA; Andreassen, HF; Armbruster, K; Bangsborg, J; Bodtger, U; Browatzki, A; Christensen, CW; Coia, JE; Datcu, R; Eklöf, J; Ellingsgaard, T; Fenlev, CS; Ghathian, KSA; Gundersen, L; Harboe, ZB; Heidemann, M; Janner, J; Jensen, JUS; Jensen, TT; Johansson, SL; Johnsen, S; Kjærgaard, JL; Lapperre, TS; Linde, H; Moberg, M; Nielsen, TL; Overgaard, RH; Pedersen, L; Rosenvinge, FS; Saeed, MI; Seersholm, N; Sivapalan, P; Sørensen, VM; Titlestad, I; Ulrik, CS; Vijdea, R; Weinreich, UM; Wilcke, T; Østergaard, C | 1 |
1 trial(s) available for beta-lactams and Cirrhosis
| Article | Year |
|---|---|
Targeted AntiBiotics for Chronic pulmonary diseases (TARGET ABC): can targeted antibiotic therapy improve the prognosis of Pseudomonas aeruginosa-infected patients with chronic pulmonary obstructive disease, non-cystic fibrosis bronchiectasis, and asthma?
Topics: Anti-Bacterial Agents; Asthma; beta-Lactams; Bronchiectasis; Ciprofloxacin; Fibrosis; Humans; Prednisolone; Prognosis; Pseudomonas aeruginosa; Pulmonary Disease, Chronic Obstructive | 2022 |